Literature DB >> 31899168

Sublingual microvasculature in diabetic patients.

Patricia P Wadowski1, Alexandra Kautzky-Willer2, Thomas Gremmel1, Renate Koppensteiner1, Peter Wolf2, Sebastian Ertl3, Constantin Weikert1, Christian Schörgenhofer4, Bernd Jilma5.   

Abstract

Diabetes is associated with micro- and macrovascular complications. The aim of the study was to investigate microvascular parameters (glycocalyx dimensions, perfused and total capillary density) in vivo in patients with type 1 and type 2 diabetes mellitus. In vivo sublingual videomicroscopy using sidestream darkfield - derived imaging was performed in 36 patients with diabetes mellitus (type 1: n = 20, type 2: n = 16) and compared to a control group of 36 healthy volunteers. Patients with HbA1c levels ≥ 8% had a significantly higher perfused boundary region (PBR; signifying the loss of glycocalyx dimensions) compared to patients with HbA1c levels < 8%, which was more pronounced in type 1 diabetes (2.08 μm [1.95-2.16 μm] vs.1.9 μm [1.66-1.94 μm], p = .029). Capillary density did not differ significantly between patients with diabetes and healthy controls. PBR was inversely related to RBC filling percentage and perfused capillary density in diabetic patients (r = -0.754, p < .001 and r = -0.505, p = .002, respectively) as well as in healthy volunteers (r = -0.701, p < .001 and r = -0.150, p = n.s.) signifying the association between glycocalyx dimensions and microvessel perfusion. Renal parameters were associated with microvascular perfusion in patients with type 2 diabetes (correlation between eGFR and perfused capillary density: r = 0. 568, p = .027/RBC filling percentage: r = 0.657, p = .008). In addition, the ratio of perfused/total capillary density correlated with CRP levels in type 2 diabetes (r = 0.682, p = .021). In conclusion, diabetes is associated with loss of glycocalyx density.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Glycocalyx; Microcirculation; Perfused boundary region

Mesh:

Substances:

Year:  2019        PMID: 31899168     DOI: 10.1016/j.mvr.2019.103971

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  6 in total

1.  Effect of high glucose on glycosaminoglycans in cultured retinal endothelial cells and rat retina.

Authors:  Gaganpreet Kaur; Yuefan Song; Ke Xia; Kevin McCarthy; Fuming Zhang; Robert J Linhardt; Norman R Harris
Journal:  Glycobiology       Date:  2022-07-13       Impact factor: 5.954

2.  Roles of Endovascular Calyx Related Enzymes in Endothelial Dysfunction and Diabetic Vascular Complications.

Authors:  Zhi Li; Ning Wu; Jing Wang; Quanbin Zhang
Journal:  Front Pharmacol       Date:  2020-11-30       Impact factor: 5.810

3.  Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis.

Authors:  Richard Vollenberg; Phil-Robin Tepasse; Kevin Ochs; Martin Floer; Markus Strauss; Florian Rennebaum; Iyad Kabar; Alexandros Rovas; Tobias Nowacki
Journal:  Viruses       Date:  2021-11-21       Impact factor: 5.048

4.  Assessment of sublingual microcirculation for the screening of diabetic nephropathy.

Authors:  Qiang Li; XiaoXiao Liu; Mengxiao Jia; Fang Sun; Yingsha Li; Hexuan Zhang; Xiaoli Liu; Hongbo He; Zhigang Zhao; Zhencheng Yan; Zhiming Zhu
Journal:  Diabetol Metab Syndr       Date:  2022-07-06       Impact factor: 5.395

5.  A possible pathogenic role of Syndecan-1 in the pathogenesis of coronavirus disease 2019 (COVID-19).

Authors:  Sajad Karampoor; Hamid Zahednasab; Mohammad Farahmand; Rasoul Mirzaei; Farhad Zamani; Alireza Tabibzadeh; Behnaz Bouzari; Hossein Ajdarkosh; Mehdi Nikkhah; Melika Razavi Hashemi; Azadeh Laali; Hossein Keyvani
Journal:  Int Immunopharmacol       Date:  2021-04-17       Impact factor: 5.714

Review 6.  Glycocalyx as Possible Limiting Factor in COVID-19.

Authors:  Patricia P Wadowski; Bernd Jilma; Christoph W Kopp; Sebastian Ertl; Thomas Gremmel; Renate Koppensteiner
Journal:  Front Immunol       Date:  2021-02-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.